Cargando…

Survival benefit after neoadjuvant or adjuvant radiotherapy for stage II–III gastroesophageal junction adenocarcinoma: A large population-based cohort study

OBJECTIVE: The standard treatment for stage II–III gastroesophageal junction adenocarcinoma (GEJA) remains controversial, and the role of radiotherapy (RT) in stage II–III GEJA is unclear. Herein, we aimed to evaluate the prognosis of different RT sequences and identify potential candidates to under...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zuo, Zhichao, Peng, Yafeng, Zeng, Ying, Lin, Shanyue, Zeng, Weihua, Zhou, Xiao, Zhou, Yinjun, Li, Bo, Ma, Jie, Long, Mingju, Cao, Shenghui, Liu, Yang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630344/ https://www.ncbi.nlm.nih.gov/pubmed/36338703 http://dx.doi.org/10.3389/fonc.2022.998101

Ejemplares similares

Concurrent Neoadjuvant Chemoradiotherapy for Siewert II and III Adenocarcinoma at Gastroesophageal Junction
por: Zhao, Qun, et al.
Publicado: (2015)

Neoadjuvant radiotherapy for locoregional Siewert type II gastroesophageal junction adenocarcinoma: A propensity scores matching analysis
por: Zhou, Yuan, et al.
Publicado: (2021)

Identification of Sensitivity Predictors of Neoadjuvant Chemotherapy for the Treatment of Adenocarcinoma of Gastroesophageal Junction
por: Li, Shoumiao, et al.
Publicado: (2017)

Significance of Neoadjuvant Downstaging in Carcinoma of Esophagus and Gastroesophageal Junction
por: Kamarajah, S. K., et al.
Publicado: (2020)

Neoadjuvant Chemoradiotherapy versus Chemotherapy for Gastroesophageal Junction Adenocarcinoma; Which Is the Optimal Treatment Option?
por: Zandirad, Eric, et al.
Publicado: (2022)

Adjuvant Chemoradiotherapy Versus Adjuvant Chemotherapy for Stage III Gastric or Gastroesophageal Junction Cancer After D2/R0 Resection
por: Shi, Jinming, et al.
Publicado: (2022)

Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm phase 2 trial
por: Wei, Jia, et al.
Publicado: (2023)

Adjuvant chemoradiotherapy vs adjuvant chemotherapy in locally advanced Siewert type II/III adenocarcinoma of gastroesophageal junction after D2/R0 resection
por: Kang, Wen-Zhe, et al.
Publicado: (2022)

Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
por: Tian, Yuan, et al.
Publicado: (2021)

Relevant issues in tumor regression grading of histopathological response to neoadjuvant treatment in adenocarcinomas of the esophagus and gastroesophageal junction
por: Klevebro, F, et al.
Publicado: (2020)

Gastroesophageal junction adenocarcinoma metastasizing to gingiva
por: Masamatti, Smita S, et al.
Publicado: (2013)

Epidemiology of Gastroesophageal Junction Adenocarcinoma in Korea
por: Kim, Jin-Jo
Publicado: (2018)

Neoadjuvant Treatment Strategies for Resectable Proximal Gastric, Gastroesophageal Junction and Distal Esophageal Cancer
por: Ahmad, M. Usman, et al.
Publicado: (2022)

Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or the gastroesophageal junction: A meta-analysis based on clinical trials
por: Zhao, Xin, et al.
Publicado: (2018)

Fever of Undetermined Origin During Neoadjuvant Chemoradiotherapy of Gastroesophageal Junction Adenocarcinoma Due to Radiation-induced Liver Disease
por: Bashir, Babar, et al.
Publicado: (2019)

Independent Stage Classification for Gastroesophageal Junction Adenocarcinoma
por: Hirata, Yuki, et al.
Publicado: (2023)

The Incidence of Free Peritoneal Tumor Cells before and after Neoadjuvant Chemotherapy in Gastroesophageal Junction Cancer
por: Strandby, Rune B., et al.
Publicado: (2020)

Impact of neoadjuvant FLOT treatment of advanced gastric and gastroesophageal junction cancer following surgical therapy
por: Paszt, Attila, et al.
Publicado: (2023)

KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma
por: Tabernero, Josep, et al.
Publicado: (2021)

Radiotherapy for tumors of the stomach and gastroesophageal junction – a review of its role in multimodal therapy
por: Buergy, Daniel, et al.
Publicado: (2012)

Relevance of Position and Movement of the Gastroesophageal Junction in Gastroesophageal Reflux Disease
por: Lee, Yeong Yeh
Publicado: (2013)

Factors associated with pathologic complete response following neoadjuvant chemoradiation and esophagectomy for carcinoma of esophagus and gastroesophageal junction
por: Nusrath, Syed, et al.
Publicado: (2022)

Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma
por: Faron, Matthieu, et al.
Publicado: (2023)

Survival benefit of adjuvant radiotherapy in stage III and IV bladder cancer: results of 170 patients
por: Bayoumi, Yasser, et al.
Publicado: (2014)

Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
por: Gil-Delgado, Maria Angeles, et al.
Publicado: (2018)

Treatment for metastatic adenocarcinoma of the stomach and gastroesophageal junction: 2020
por: Hsu, Andrew, et al.
Publicado: (2020)

Treatment Patterns for Gastroesophageal Junction Adenocarcinoma in the United States †
por: Kim, Bradford J., et al.
Publicado: (2020)

Adenocarcinoma of the Gastroesophageal Junction Masquerading as Mallory-Weiss Syndrome
por: Okamoto, Takeshi, et al.
Publicado: (2022)

Mediastinal Lymph Node Dissection in Gastroesophageal Junction Adenocarcinoma
por: Kim, Jin-Jo
Publicado: (2023)

The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction
por: Tang, Zhaoqing, et al.
Publicado: (2022)

RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV
por: Lorenzen, Sylvie, et al.
Publicado: (2020)

Neoadjuvant and Adjuvant Therapy in Intrahepatic Cholangiocarcinoma
por: Chen, Xing, et al.
Publicado: (2022)

Benefit of adjuvant chemoradiotherapy in patients with pathological stage III gastric cancer
por: Ma, Gui-Fen, et al.
Publicado: (2019)

Clinical management of gastroesophageal junction tumors: past and recent evidences for the role of radiotherapy in the multidisciplinary approach
por: Cellini, Francesco, et al.
Publicado: (2014)

Benefits of an Immunogenic Personalized Neoantigen Nanovaccine in Patients with High‐Risk Gastric/Gastroesophageal Junction Cancer
por: Liu, Qin, et al.
Publicado: (2022)

The optimal neoadjuvant chemotherapy regimen for locally advanced gastric and gastroesophageal junction adenocarcinoma: a systematic review and Bayesian network meta-analysis
por: Wang, Tongya, et al.
Publicado: (2022)

Surgical Treatment of Gastroesophageal Junction Cancer
por: Hashimoto, Tadayoshi, et al.
Publicado: (2018)

Meningeal Carcinomatosis: A Metastasis from Gastroesophageal Junction Adenocarcinoma
por: Dam, Tanya, et al.
Publicado: (2013)

Incidence of Microscopically Positive Proximal Margins in Adenocarcinoma of the Gastroesophageal Junction
por: Gao, Fei, et al.
Publicado: (2014)

Signaling pathways in the molecular pathogenesis of adenocarcinomas of the esophagus and gastroesophageal junction
por: Clemons, Nicholas J, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_pvnbu1j0k9rlu9kpkakud1d106